21:59 , Jul 11, 2019 |  BC Innovations  |  Targets & Mechanisms

The tumor stroma rises as the newest source of immuno-oncology targets

With a spate of therapies entering the clinic, the next frontier in the fight against resistance to checkpoint inhibitors will be the stroma. The lead target marks a resurgence of interest in TGFβ, and behind...
17:39 , Sep 26, 2018 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Alzheimer’s disease (AD) Cell culture and mouse studies suggest inhibiting Rho kinase could help to treat AD. In primary rat cortical neurons stimulated with DKK1 to produce β amyloid, the Rho kinase inhibitor Eril...
15:11 , May 4, 2018 |  BC Week In Review  |  Clinical News

Leap reports Phase I data from DKN-01 plus Keytruda arm in esophageal cancer

Leap Therapeutics Inc. (NASDAQ:LPTX) reported data from seven evaluable patients with advanced esophagogastric cancer in the Phase I P102 trial showing that DKN-01 on days one and 15 of each 21-day cycle plus PD-1 inhibitor...
17:59 , Apr 13, 2018 |  BC Week In Review  |  Clinical News

Leap reports Phase I data from monotherapy arm of esophageal cancer trial

Leap Therapeutics Inc. (NASDAQ:LPTX) reported data from 16 patients with advanced esophagogastric cancer in the Phase I P102 trial showing that DKN-01 as monotherapy led to two partial responses, plus five cases of stable disease....
21:05 , Dec 8, 2017 |  BC Week In Review  |  Financial News

ALK-Abelló raises DKK698.9M in private placement

On Dec. 7, ALK-Abelló A/S (CSE:ALK-B) raised DKK698.9 million ($111.5 million) through the sale of 1 million shares at DKK690 in an oversubscribed private placement led by Danske Bank. Other undisclosed investors also participated. ALK...
00:44 , Dec 8, 2017 |  BC Extra  |  Financial News

ALK-Abelló raises DKK698.9M

ALK-Abelló A/S (CSE:ALK-B) raised DKK698.9 million ($111.5 million) through the sale of 1 million shares at DKK690 in an oversubscribed private placement. ALK said the funds will help finance its DKK1 billion ($160 million), three-year...
20:27 , Feb 3, 2017 |  BC Week In Review  |  Company News

Novo Nordisk, University of Oxford deal

Novo Nordisk and the university created the Novo Nordisk Research Centre Oxford to discover targets for Type II diabetes. Novo Nordisk will invest DKK1 billion ($143.8 million) into the center over 10 years. The center...
00:01 , Nov 22, 2016 |  BC Extra  |  Company News

Quick FDA approval for Darzalex in second-line MM

Genmab A/S (CSE:GEN) said FDA approved Darzalex daratumumab in combination with dexamethasone and either Revlimid lenalidomide or Velcade bortezomib to treat multiple myeloma in patients who have received at least one prior therapy. The approval...
07:00 , Oct 24, 2016 |  BC Week In Review  |  Clinical News

DKN-01: Phase I data

Top-line data from a 2-part, open-label, U.S. Phase I trial in 27 patients with cholangiocarcinoma showed that 150 and 300 mg doses of IV DKN-01 plus gemcitabine and cisplatin on days 1 and 8 of...
07:00 , Sep 5, 2016 |  BC Week In Review  |  Company News

Leap Therapeutics, Macrocure deal

Leap will merge with Macrocure in a deal that will create a publicly listed company with two clinical-stage immuno-oncology candidates. Leap’s DKN-01 , a mAb against dickkopf homolog 1 (DKK1) , is in Phase I/II...